Chronic Rhinosinusitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Phenotype (Non-Eosinophilic Chronic Rhinosinusitis, Eosinophilic Chronic Rhinosinusitis, Infectious Chronic Rhinosinusitis, Allergic Fungal Rhinosinusitis, Others), By Treatment Type (Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.12 Billion
CAGR (2026-2031)	7.33%
Fastest Growing Segment	Eosinophilic Chronic Rhinosinusitis
Largest Market	North America
Market Size (2031)	USD 4.77 Billion

Market Overview

The Global Chronic Rhinosinusitis Market will grow from USD 3.12 Billion in 2025 to USD 4.77 Billion by 2031 at a 7.33% CAGR. Chronic Rhinosinusitis (CRS) is defined as a persistent inflammation of the mucosa within the nasal cavity and paranasal sinuses lasting for at least twelve consecutive weeks, often characterized by nasal obstruction, facial pressure, and hyposmia. The primary drivers supporting market growth include the escalating prevalence of respiratory allergies and increasing environmental pollution, both of which heighten susceptibility to sinonasal inflammation. Additionally, the expanding geriatric population significantly fuels demand, as age-related physiological changes frequently exacerbate chronic sinus conditions. According to the American Academy of Otolaryngology–Head and Neck Surgery Foundation, in 2025, chronic rhinosinusitis affected 11.6% of adults and prompted 4.1 million annual ambulatory visits.

A significant challenge impeding the rapid expansion of the Global Chronic Rhinosinusitis Market is the substantial cost associated with advanced biologic therapies and minimally invasive surgical interventions. Although these innovative treatments offer superior efficacy for refractory cases, their high price points often create barriers to access and reimbursement, particularly in price-sensitive developing regions. Consequently, economic constraints may limit the widespread adoption of these premium therapeutic options, thereby moderating the overall revenue potential of the sector.

Key Market Drivers

Accelerated Adoption of Targeted Biologic Therapies for Nasal Polyps is significantly altering the clinical management of chronic rhinosinusitis for refractory cases. These novel agents target specific inflammatory pathways, offering a potent non-surgical alternative for reducing polyp burden and restoring olfactory function. The market is experiencing a swift integration of these therapies as clinical guidelines increasingly endorse their use for patients who fail to respond to corticosteroids. According to Regeneron Pharmaceuticals, October 2024, in the 'Third Quarter 2024 Financial and Operating Results', global net sales for Dupixent, a key biologic in this space, increased by 23% to $3.82 billion, reflecting robust commercial demand. This revenue growth underscores the shift towards precision medicine in addressing Type 2 inflammation-driven sinonasal disorders.

Simultaneously, Advancements in Minimally Invasive Sinus Surgical Procedures are expanding the market by offering safer, office-based interventions. Technologies such as balloon sinus dilation and steroid-eluting implants have minimized recovery times, encouraging broader patient acceptance. Underpinning this demand is the substantial disease burden; according to the journal Clinical & Experimental Allergy, November 2024, in the article 'Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review', the global pooled prevalence of chronic rhinosinusitis was found to be 8.71%, indicating a vast patient population requiring effective management. Consequently, device manufacturers are capitalizing on this need. According to Stryker, January 2025, in the 'Fourth Quarter and Full Year 2024 Operating Results', the MedSurg and Neurotechnology segment, which houses the ENT business, reported net sales of $13.5 billion, reflecting an 11.1% increase driven by sustained procedural demand.

Download Free Sample Report

Key Market Challenges

The substantial financial burden associated with advanced biologic therapies and minimally invasive surgical interventions presents a formidable barrier to the growth of the Global Chronic Rhinosinusitis Market. While these modalities provide significant clinical benefits for refractory patients, their prohibitive pricing structures restrict widespread accessibility. Healthcare systems, particularly in regions with finite resources, often struggle to accommodate these premium costs, leading to stringent reimbursement policies and limited formulary inclusion. Consequently, the adoption rate of these therapies is dampened as patients and providers are forced to rely on less expensive, conventional treatments that may be less effective for severe cases.

The economic impact of these premium interventions is quantifiable and creates hesitation among payers. According to the European Rhinologic Society's official publication 'Rhinology', in 2025, the mean direct cost per patient per year for biological treatment approaches reached approximately 60,026 EUR, markedly exceeding standard surgical interventions. Such high expenditure levels deter insurance providers from authorizing these treatments as first-line options. This financial friction directly curtails the revenue volume that manufacturers could otherwise realize, effectively moderating the overall expansion of the market despite the clear clinical demand for improved therapeutic outcomes.

Key Market Trends

The Development of Novel Sustained-Release Intranasal Delivery Systems is addressing the limitations of conventional sprays and implants. These exhalation delivery systems utilize the patient’s breath to propel medication deep into sinonasal cavities, improving drug deposition without invasive procedures. This mechanism is gaining traction among specialists seeking to optimize topical steroid efficacy. Evidence of this adoption is visible in the commercial performance of niche innovators. According to Optinose, January 2025, in the 'Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue' press release, the company reported net product revenue of $22.4 million for the quarter, reflecting sustained demand for its novel delivery platform.

Simultaneously, the Integration of Augmented Reality in Endoscopic Sinus Surgery is enhancing visualization and anatomical precision. Surgeons are increasingly adopting navigation systems that overlay three-dimensional anatomical data onto the surgical field, reducing complication risks during complex procedures. This trend aligns with the industry's push for high-precision interventions that minimize tissue trauma. Consequently, demand for advanced capital equipment remains robust as hospitals upgrade surgical suites. According to Medtronic, May 2024, in the 'Full Year and Fourth Quarter Fiscal 2024 Financial Results', the Specialty Therapies division reported high-single digit growth in the ENT business, driven by strength in power capital and navigation technologies.

Segmental Insights

Based on current industry analysis, Eosinophilic Chronic Rhinosinusitis represents the fastest-growing segment within the global market, primarily driven by its recalcitrant nature and the emergence of precision medicine. Unlike other phenotypes, this condition is characterized by severe Type 2 inflammation and high recurrence rates, often resisting conventional surgical or corticosteroid treatments. Consequently, the market is shifting toward advanced therapeutic interventions. This growth is heavily supported by the introduction of FDA-approved biologic therapies, such as monoclonal antibodies, which specifically target underlying inflammatory pathways. The increasing clinical adoption of these targeted treatments for refractory cases is significantly accelerating the expansion of this segment.

Regional Insights

North America dominates the global chronic rhinosinusitis market primarily due to the high prevalence of nasal disorders and robust healthcare infrastructure. The region benefits from favorable reimbursement policies that improve patient access to essential treatments. Additionally, the strong presence of major market players fosters continuous product development. The United States Food and Drug Administration supports this growth by facilitating the approval of new therapeutic options. These combined factors ensure North America remains the leading region for chronic rhinosinusitis management and treatment solutions.

Recent Developments

• In January 2025, GSK announced that China’s National Medical Products Administration had approved Nucala for use in adults with chronic rhinosinusitis with nasal polyps. This regulatory clearance allows the interleukin-5 inhibitor to be prescribed as an add-on therapy for patients whose condition remains uncontrolled despite intranasal corticosteroids or prior surgical intervention. The approval was largely supported by results from the Phase 3 MERIT trial, which evaluated the drug in patients across China and other nations. This milestone represents a strategic expansion for the company, addressing a significant unmet medical need within the growing Chinese respiratory market.
• In November 2024, Amgen and AstraZeneca announced positive topline findings from the Phase 3 WAYPOINT trial investigating the efficacy of Tezspire in patients with severe chronic rhinosinusitis with nasal polyps. The study achieved its co-primary endpoints, demonstrating that the treatment resulted in a statistically significant reduction in nasal polyp size and nasal congestion compared to placebo. These results validated the mechanism of targeting thymic stromal lymphopoietin to mitigate epithelial-driven inflammation. The companies noted that the safety profile was consistent with established data, positioning the biologic as a promising potential treatment for those suffering from this chronic inflammatory condition.
• In September 2024, Regeneron Pharmaceuticals and Sanofi announced that the US Food and Drug Administration had expanded the indication for Dupixent to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps. This approval distinguished the therapy as the first biologic medicine sanctioned for this specific patient population in the United States. The decision relied on the extrapolation of efficacy data from extensive adult trials, complemented by safety and pharmacokinetic evaluations in younger patients. This development provided a critical new therapeutic option for adolescents who continue to experience debilitating symptoms despite previous treatment with systemic corticosteroids or surgery.
• In March 2024, Optinose received approval from the US Food and Drug Administration for Xhance nasal spray to treat chronic rhinosinusitis without nasal polyps in adults. This regulatory decision marked a significant development in the market, as the product became the first prescription medication authorized specifically for this widespread indication. The approval was based on positive results from the ReOpen clinical program, which comprised two Phase 3 trials showing statistically significant symptom reduction. The treatment utilizes a unique exhalation delivery system to transport fluticasone propionate to the upper nasal passages, addressing inflammation in areas typically difficult to reach with standard nasal sprays.

Key Market Players

• Lyra Therapeutics
• Novartis AG
• Medtronic plc
• GlaxoSmithKline plc
• AstraZeneca Plc
• Sanofi AG
• Dr. Reddy's Laboratories Ltd.
• Stryker Corporation
• Bayer AG
• Smith & Nephew Plc

By Disease Phenotype	By Treatment Type	By Distribution Channel	By Region
Non-Eosinophilic Chronic Rhinosinusitis Eosinophilic Chronic Rhinosinusitis Infectious Chronic Rhinosinusitis Allergic Fungal Rhinosinusitis Others	Medical Devices Drugs Nasal Drops Steroid Nasal Sprays Surgery Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Chronic Rhinosinusitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chronic Rhinosinusitis Market, By Disease Phenotype:

• Non-Eosinophilic Chronic Rhinosinusitis
• Eosinophilic Chronic Rhinosinusitis
• Infectious Chronic Rhinosinusitis
• Allergic Fungal Rhinosinusitis
• Others

• Chronic Rhinosinusitis Market, By Treatment Type:

• Medical Devices
• Drugs
• Nasal Drops
• Steroid Nasal Sprays
• Surgery
• Others

• Chronic Rhinosinusitis Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Chronic Rhinosinusitis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE